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Abstract
Background: Childhood asthma is strongly influenced by genetics and is a risk factor for reduced lung function
and chronic obstructive pulmonary disease (COPD) in adults. This study investigates self-reported childhood asthma
in adult smokers from the COPDGene Study. We hypothesize that childhood asthma is associated with decreased
lung function, increased risk for COPD, and that a genome-wide association study (GWAS) will show association
with established asthma variants.
Methods: We evaluated current and former smokers ages 45–80 of non-Hispanic white (NHW) or African American
(AA) race. Childhood asthma was defined by self-report of asthma, diagnosed by a medical professional, with onset
at < 16 years or during childhood. Subjects with a history of childhood asthma were compared to those who never
had asthma based on lung function, development of COPD, and genetic variation. GWAS was performed in NHW
and AA populations, and combined in meta-analysis. Two sets of established asthma SNPs from published literature
were examined for association with childhood asthma.
Results: Among 10,199 adult smokers, 730 (7%) reported childhood asthma and 7493 (73%) reported no history of
asthma. Childhood asthmatics had reduced lung function and increased risk for COPD (OR 3.42, 95% CI 2.81–4.18).
Genotype data was assessed for 8031 subjects. Among NHWs, 391(7%) had childhood asthma, and GWAS identified
one genome-wide significant association in KIAA1958 (rs59289606, p = 4.82 × 10− 8). Among AAs, 339 (12%) had
childhood asthma. No SNPs reached genome-wide significance in the AAs or in the meta-analysis combining NHW
and AA subjects; however, potential regions of interest were identified. Established asthma SNPs were examined,
seven from the NHGRI-EBI database and five with genome-wide significance in the largest pediatric asthma GWAS.
Associations were found in the current childhood asthma GWAS with known asthma loci in IL1RL1, IL13, LINC01149,
near GSDMB, and in the C11orf30-LRRC32 region (Bonferroni adjusted p < 0.05 for all comparisons).
Conclusions: Childhood asthmatics are at increased risk for COPD. Defining asthma by self-report is valid in
populations at risk for COPD, identifying subjects with clinical and genetic characteristics known to associate
with childhood asthma. This has potential to improve clinical understanding of asthma-COPD overlap (ACO)
and enhance future research into ACO-specific treatment regimens.
Trial registration: ClinicalTrials.gov, NCT00608764 (Active since January 28, 2008).
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Background
Asthma is the most common chronic disease of child-
hood, affecting 8.4% of children in the United States [1].
Childhood asthma is a genetically distinct asthma subtype,
with estimated heritability of 68–92% [2–10]. Asthma is a
known risk factor for development of reduced lung func-
tion and chronic obstructive pulmonary disease (COPD)
in adults [11–14]. Asthmatics are often excluded from
COPD studies, and thus information on the mechanism
of disease and appropriate treatments for asthma-COPD
overlap (ACO) remains limited [15].
We have previously examined self-reported history of
childhood asthma and ACO in the COPDGene Study, a
cohort of more than 10,000 adult smokers with and
without COPD. We have shown that a combined history
of childhood pneumonia with childhood asthma is a risk
factor for developing COPD [16]. We demonstrated that
that ACO subjects were younger with a lower lifetime
smoking intensity, and that both childhood asthmatics
and ACO subjects have increased airways disease on chest
computed tomography scan [17–19]. Longitudinal analysis
has shown that early-life asthmatics do not have increased
rates of lung function decline despite their increased ex-
acerbation frequency [20]. We have not previously exam-
ined childhood asthma as an independent risk factor for
COPD in this population.
As interest in the long-term outcomes of early-life
asthmatics has expanded, a recurring question has risen
about the validity of using self-reported asthma history
in large adult cohorts recruited for genetic epidemiology
studies [21, 22]. This has been particularly important when
trying to understand Asthma-COPD Overlap (ACO), as
epidemiologic studies of COPD, an adult disease, rely
on self-reported history of asthma early in life both for
exclusion criteria and for analysis [15, 23]. Our current
investigation examines self-reported childhood asthma
in adult smokers from the COPDGene Study, to see if
they share similar phenotypes and genotypes with those
seen in asthmatic subjects from prior studies, including
published GWAS [2, 3, 24]. Prior GWAS have implicated
genetic susceptibility specific to childhood asthma, includ-
ing variants in ORMDL3/GSDMB, IL1RL1, IL33, and
RAD50 [4, 7, 24]. We hypothesize that self-reported history
of childhood asthma will be associated with decreased lung
function and increased risk for COPD in adult smokers,
and that a genome-wide association study (GWAS) will
show an increased prevalence of known asthma variants
among childhood asthmatics, compared to those subjects
who never had asthma.
Methods
Subjects
We evaluated 10,199 current and former adult smokers
enrolled in the COPDGene Study between 2008 and
2011 (August 31, 2016 dataset). The COPDGene Study
is a multicenter, observational study designed to identify
genetic and environmental factors associated with
COPD. Subjects included were of non-Hispanic (NHW)
white or African American (AA) race, between 45 and
80 years of age, and had at least a 10 pack-year history
of smoking. We excluded subjects with lung disease
other than asthma or COPD, or those who were non-
smokers. Subjects were recruited at 21 clinical sites
within the U.S. Each site received institutional review
board approval and each participant provided informed
consent [25]. Details of the study protocol and data
forms are available at www.copdgene.org [25, 26].
Data collection
Subject responses to a modified American Thoracic
Society Respiratory Epidemiology Questionnaire were
used to collect asthma history [26, 27]. A standardized
spirometry protocol pre and post-albuterol was com-
pleted (ndd EasyOne Spirometer, Zurich, Switzerland).
DNA extracted from blood samples was genotyped
using HumanOmniExpress arrays (Illumina, San Diego,
CA). DNA and single nucleotide polymorphism (SNP)
data underwent standard quality control measures [25, 28,
29]. Imputation used 1000 Genomes Phase I v3 reference
panels (hg19) to obtain additional genotypes with MaCH
and minimac (exomeChip pipelineV1.4) [29–32]. Imput-
ation quality was assessed using Rsq, and SNPs with Rsq
> 0.3 were considered to be of acceptable quality. COPD-
Gene datasets are publicly available (dbGaP accession
number phs000179.v1.p1).
Case identification
Asthma history was assessed by questionnaire response.
Subjects were asked if they had ever had asthma, at
what age it started, and if it was diagnosed by a doctor
or other health professional. Childhood asthma was de-
fined as self-report of asthma diagnosed by a health
professional with age of onset at < 16 years or as a child
with exact age not known [5, 16, 20, 33]. Subjects were
classified as never having asthma if they responded
“No” to asthma history on the questionnaire. As in pre-
vious COPDGene publications, COPD was defined as
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) 2007 spirometry grades 2–4, corresponding to
post-bronchodilator forced expiratory volume in the
first second (FEV1) to forced vital capacity (FVC) ratio
< 0.7 with FEV1 < 80% predicted [16–18, 20, 34]. Con-
trol smokers had normal spirometry, defined as FEV1/
FVC ≥ 0.7 and FEV1 ≥ 80%.
Statistical analysis
Subjects with childhood asthma were compared to sub-
jects who never had asthma on measures of lung function
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and development of COPD. Subjects with missing or
unclassifiable responses were removed from the specific
analysis. Statistical analysis used R v3.1.1. Single vari-
able analysis used chi-square tests, Wilcoxon rank sum
tests, or t-tests. Multivariable regression analysis was
performed, all models were adjusted for number of
pack years of smoking history. COPD and FEV1/FVC
models were additionally adjusted for gender, age at
enrollment, and race. The FEV1/FVC model was also
adjusted for height; percent predicted FEV1 and FVC
values have these factors accounted for in the baseline
variable thus no adjustment was indicated. Logistic re-
gression reported odds ratio (OR) with 95% confidence
interval (CI) and linear regression reported absolute
difference (β) with standard error (SE).
GWAS were performed comparing those with history
of childhood asthma to those who never had asthma
using PLINK 1.90 [35]. GWAS were performed in the
NHW and AA populations separately using logistic re-
gression adjusted for sex and principal components (PC)
for genetic ancestry [28]. SNPs were considered to reach
genome-wide significance at the threshold of p ≤ 5 × 10− 8,
and regions of interest were identified at near genome-
wide significance with p ≤ 1 × 10− 6 [36, 37]. The degree
of genomic inflation after PC adjustment was assessed
[38]. Results from the NHW and AA populations were
combined in a fixed effects meta-analysis with inverse
variance weighting [35, 39].
Comparison to published asthma GWAS
The childhood asthma GWAS results were examined for
association with established asthma SNPs derived from the
National Human Genome Research Institute - European
Bioinformatics Institute (NHGRI-EBI) Catalog of pub-
lished genome-wide association studies (Sept 28, 2017
search, https://www.ebi.ac.uk/gwas/search) [2, 3]. A
search for the disease/trait “asthma” identified 85 studies,
with 600 SNP associations. Eight SNPs were identified in
more than one NHGRI-EBI catalog study, and were con-
sidered established asthma SNPs: rs10197862 in IL1RL1,
rs1837253 near TSLP, rs2244012 in RAD50, rs1295686
in IL13, rs7130588 near the C11orf30-LRRC32 region,
rs3894194 in GSDMA, rs2305480 and rs11078927 in
GSDMB [7, 40–50]. Two GSDMB SNPs were in high link-
age disequilibrium (r2 > 0.8). We selected the SNP that
was genotyped in our population, rs2305480, for inclusion,
and rs11078927 was excluded, leaving seven established
asthma SNPs. These seven established asthma SNPs were
examined for association with childhood asthma in the
current GWAS, with a Bonferroni correction for seven
tests performed, and a significance level of 0.05. Hyper-
geometric testing was used to calculate the likelihood that
the established asthma SNPs were over-represented in this
sample.
The childhood asthma GWAS results were addition-
ally examined for association with the five genetic loci
found to be associated with pediatric asthma in the lar-
gest pediatric asthma GWAS to date (8976 cases, 18,399
controls) from the Trans-National Asthma Genetic Con-
sortium (TAGC): rs4988958 in IL1RL1, rs1295685 in IL13,
rs2596464 in LINC01149, rs12551256 in IL33, rs8069176
near GSDMB [24]. These five TAGC pediatric asthma
SNPs were examined for association with childhood
asthma in the current GWAS, with a Bonferroni cor-
rection for five tests performed, and a significance
level of 0.05.
Results
Subject classification
Of 10,199 subjects in the COPDGene study, 730 (7%)
had childhood asthma and 7493 (73%) were control sub-
jects without childhood asthma (Table 1). There were
1976 subjects removed from the analysis: 52 with re-
sponses to the childhood asthma questions that were
not classifiable, 1229 who reported a history of asthma
that did not start in childhood, and 695 who reported
they did not know if they had asthma (Additional file 1:
Figure S1).
Subject characteristics
Compared to subjects without childhood asthma, those
with history of childhood asthma were younger and more
likely to be AA. Subjects with childhood asthma had in-
creased odds of developing COPD (OR 3.42, 95% CI
2.81–4.18) (Table 2). When compared to those without
childhood asthma, adult smokers with asthma during
childhood also had reduced lung function measured by
FEV1, FVC and FEV1/FVC (p < 0.001 for all comparisons).
GWAS
Genotype data was assessed in 8031 subjects who met
case/control criteria (Additional file 1: Figure S1). Among
the 5364 NHWs, there were 385 (7%) childhood asthma
Table 1 Characteristics of childhood asthma subjects compared
to subjects without asthma in COPDGene
Childhood Asthma Never Asthma P-value
N = 730 N = 7493
Male gender (%)a 388 (53%) 4255 (57%) 0.06
Mean age, year (SD)c 58 (9) 60 (9) < 0.001
Non-Hispanic white (%)a 391 (54%) 5075 (68%) < 0.001
African American (%)a 339 (46%) 2418 (32%) < 0.001
Pack-years of smoking
(SD)b
43 (25) 44 (25) 0.09
Current smoking (%)a 410 (56%) 4041 (54%) 0.26
History of hay fever (%)a 385 (53%) 1727 (23%) < 0.001
Univariate analysis with a Chi-square b Wilcoxon rank sum test c t-test
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cases and 4979 (93%) controls without childhood asthma.
Among the 2667 AAs, there were 325 (12%) childhood
asthma cases and 2342 (88%) controls. NHW and AA
GWAS included all SNPs with minor allele frequency
(MAF) ≥ 5%, Quantile-Quantile (QQ) and Manhattan
plots including can be viewed in Additional file 1: Figure
S2 and S3. Lambda values were 1.01 in both NHW and
AA populations. Meta-analysis included all SNPs with
MAF ≥ 1%, with a lower MAF cutoff used to account for
the more modest correlation of variants between ances-
tries; QQ and Manhattan plots are in Additional file 1:
Figure S4 [39, 51].
In the NHW childhood asthma GWAS, one SNP
reached the level of genome-wide significance, rs59289606
located in the gene KIAA1958 (p = 4.82 × 10− 8) (Table 3,
Fig. 1, Additional file 1: Figure S2). An additional re-
gion of interest was identified in PDZD2 with three
SNPs approaching genome-wide significance (p = 3.9–
7.80 × 10− 7) (Additional file 1: Figure S5). In the AA
childhood asthma GWAS, no SNPs reached the level of
genome-wide significance, however, regions of interest
were identified in FLJ12825 (p = 1.75 × 10− 7) and PHF14
(p = 4.94 × 10− 7) (Additional file 1: Figure S6). Meta-
analysis combined the NHW and AA results from this
study. No meta-analysis SNPs reached the level of
genome-wide significance. However, a region of interest
was identified in SCHIP1 and its read through transcript
IQCJ-SCHIP1 with 14 SNPs approaching genome-wide
significance (p = 2.39–7.84 × 10− 7) (Fig. 1).
Association testing of established asthma variants
Seven NHGRI-EBI SNPs previously known to be asso-
ciated with asthma were extracted from the current
GWAS results (Table 4). Among the NHW population,
the childhood asthma GWAS found association with a
known asthma variants in IL1RL1 (rs10197862, adjusted
p = 0.011) and approached significance in GSDMB
(rs2305480, adjusted p = 0.060) and near the C11orf30-
LRRC32 region (rs7130588, adjusted p = 0.054) (Additional
file 1: Figure S7). The meta-analysis of NHW and AA
subjects in our childhood asthma GWAS found association
with known asthma variants in IL1RL1 (rs10197862, ad-
justed p = 0.042), in IL13 (rs1295686, adjusted p = 0.043),
and near the C11orf30-LRRC32 region (rs7130588, adjusted
p = 0.005) (Additional file 1: Figure S8). There is agreement
in direction of effect in these four associated or near associ-
ated SNPs in both NHW and AA populations as well as
with prior published GWAS [7, 40, 44, 45, 49, 50]. Hyper-
geometric testing showed that when selecting seven SNPs
from the meta-analysis population, the probability of having
one or more SNP significant at this level was p = 0.034.
Among the meta-analysis population, when selecting seven
SNPs, the probability of having three or more SNP signifi-
cant at this level was p = 1.21 × 10− 05.
Five SNPs associated with pediatric asthma in the
TAGC GWAS were examined within the current GWAS
results (Additional file 1: Table S1). Reported p-values
were Bonferroni corrected for five tests, with a signifi-
cance level of 0.05. Among the NHW population, the
childhood asthma GWAS found association with TAGC
pediatric asthma SNPs in IL1RL1 (rs4988958, adjusted p
= 0.002), LINC01149 (rs2596464, adjusted p = 0.021),
and near the GSDMB region (rs8069176, adjusted p =
0.041). The meta-analysis of NHW and AA subjects in
out childhood asthma GWAS found association with
IL1RL1 (rs4988958, adjusted p = 0.035) and LINC01149
(rs2596464, adjusted p = 0.017).
Discussion
This analysis is the first to demonstrate that a self-reported
history of childhood asthma is a valid method for defining a
population that phenotypically and genetically represent
asthmatic subjects among a cohort of adult smokers at risk
for COPD. When compared to those who never had
asthma, self-reported childhood asthmatics were younger
at study enrollment, more likely to be of AA race, and had
decreased lung function with greater odds of developing
COPD. Three of seven established NHGRI-EBI asthma
SNPs and three of five pediatric asthma SNPs from the
TAGS GWAS were associated with self-reported childhood
Table 2 COPD and lung function in subjects with childhood asthma compared to never asthma subjects
Childhood Never Impact of Childhood Asthma
Asthma Asthma
N = 730 N = 7493 OR 95% CI P-valuea
COPD (%)b,d, e 341 (47%) 2303 (31%) 3.42 (2.81, 4.18) < 0.001
β SE P-value
FEV1 post-bronchodilator % predicted (SD)
c,d 69% (25) 80% (26) −10.44 0.92 < 0.001
FVC post-bronchodilator % predicted (SD)c,d 83% (19) 89% (18) −6.01 0.68 < 0.001
FEV1/FVC post-bronchodilator (SD)
c,d,e,f 0.64 (0.16) 0.68 (0.16) −0.06 0.01 < 0.001
Abbreviations: COPD chronic obstructive pulmonary disease; FEV1 forced expiratory volume in the first second; SD standard deviation; FVC forced vital capacity.
aEach row is a separate model: bLogistic regression with odds ratio (OR), 95% confidence interval (CI); cLinear regression with beta coefficient (β), standard error
(SE). Covariates: dpack years; egender, age at enrollment, race; fheight
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asthma, including SNPs in IL1RL1, IL13, near the
C11orf30-LRRC32 region, in LINC01149, and near
GSDMB. Additionally, GWAS identified one variant in
KIAA1958 that was associated with childhood asthma
among NHWs with genome-wide significance. Regions
of interest were identified at near genome-wide signifi-
cance among NHWs in PDZD2, among AAs in FLJ12825
and PHF14, and on meta-analysis in SCHIP1 and its
read-through transcript IQCJ-SCHIP1.
There has been a growing interest in the risk of early
life asthmatics for developing COPD, and thus ACO, in
adulthood [15]. It has been proposed that in some child-
hood asthmatics, the risk for COPD is the result of the
lungs never achieving their expected growth and devel-
opment in early adulthood [11, 12, 16, 20, 52, 53].
Normal decline in lung function can lead to COPD since
expected maximal FEV1 is never attained. ACO has been
recognized as a distinct COPD subtype, with elevated
risk for exacerbations, increased health-care burden, and
different potential treatment modalities [54]. Research
into the mechanisms of disease and genetic susceptibility
for ACO subjects has been limited by the traditional ex-
clusion of asthmatic subjects from large COPD studies
[15]. Studies of COPD use spirometry as the accepted
COPD definition; however, ACO research has been
complicated by disagreement on a standard definition for
asthma and therefore ACO [15, 34, 54–56]. COPD
cohorts often include older adults and in many cases it is
not possible to confirm early-life diagnosis of asthma by
Global Initiative for Asthma (GINA) spirometry guidelines
or by physician records [55, 57]. Once COPD has been
diagnosed, it is difficult to use bronchodilator reactivity to
define asthma, as this can also be a feature of COPD. Use
of self-reported history of asthma has raised concern due
to the theoretical risk of misclassification bias [58].
This study confirms that childhood asthmatics who
smoke are at increased risk for developing low lung func-
tion and COPD as adults, when compared to smokers who
never had asthma. This investigation supports self-reported
diagnosis of asthma history as a valid method of identifying
early-life asthmatics, and a population of ACO subjects, in
large population cohorts at risk for COPD. This will be par-
ticularly important as researchers further examine the gen-
etic epidemiology of ACO.
There have been a number of prior asthma GWAS con-
ducted in populations of asthmatic subjects, beginning
with the GABRIEL Consortium in 2007, which focused on
populations of European ancestry, and continuing
through the recent TAGC GWAS, a meta-analysis in
ethnically diverse populations including 23,948 cases
and 118,538 controls; the TAGS GWAS included a
pediatric subgroup meta-analysis with 8976 cases and
18,399 controls [4, 24]. These asthma GWAS have used
a range of asthma definitions, including physician diagno-
sis in GABRIEL, electronic medical record information in
eMERGE, and physicians’ diagnosis and/or standardized
questionnaires in the TAGC [4, 24, 47]. A number of prior
GWAS have identified distinct genetic susceptibility for
pediatric onset asthma, particularly implicating ORLDM3/
GSDMB, IL1RL1, and IL13, which were all found to have
association with childhood asthma in the current analysis
[4, 5, 6, 7, 24, 59]. C11orf30-LRRC3, which also has
association in this GWAS, has been associated with in
pediatric asthma previously, though in prior GWAS the
primary link with asthma has been in the setting of aller-
gic disease [33, 60].
This study examined association with seven established
asthma SNPs, selected as they were the only SNPs reported
by more than one study among 85 studies in the
NHGRI-EBI GWAS catalog, and five SNPs from the largest
pediatric GWAS to date from the TAGC [2, 3, 24]. Five
genes were found to be associated with self-reported child-
hood asthma in COPDGene: IL1RL1, IL13, LINC01149,
near GSDMB, and in the C11orf30-LRRC32 region.
IL1RL1 in the 2q12.1 region is thought to be involved
in T-helper cell type 2 (TH2) inflammation including
Table 3 Top SNPs from childhood asthma GWAS in COPDGenee
Locus SNP Effect Allele OR Rsq Freq (%) P-valueb,d Gene Symbol Gene Name
NHWa 9q32 rs59289606 A 2.06 0.38 20% 4.82E-08 KIAA1958
(8,900,203 SNPs) 5p13.3 rs439399 C 1.52 0.99 22% 3.90E-07 PDZD2 PDZ domain containing 2
AAa 12q13.13 rs7315121 T 2.90 0.45 7% 1.75E-07 FLJ12825 uncharacterized LOC440101
(15,374,350 SNPs) 7p21.3 rs56317450 A 2.11 0.79 8% 4.94E-07 PHF14 PHD finger protein 14
Locus SNP Effect Allele OR Rsq
NHW, AA
Freq (%)
NHW, AA
I2 P-valuec,d Gene Symbol Gene Name
Meta-analysis
(7,658,992 SNPs)
3q25.32-q25.33 rs4679858 G 1.48 0.99, 0.98 14%, 12% 0 2.39E-07 SCHIP1
IQCJ-SCHIP1
schwannomin interacting
protein 1 & the
readthrough
Abbreviations: GWAS genome-wide association study; NHW Non-Hispanic Whites; AA African American; SNP single nucleotide polymorphism; OR odds ratio of
effect allele; Rsq estimation of imputation quality; Freq frequency of effect allele; I2 heterogeneity index; a Each population was run as an independent analysis,
and then combined in the meta-analysis: b Logistic regression based on case control status; c Fixed effect meta-analysis weighted by inverse variance. d Adjusted
for sex, genetic ancestry. e Includes the top SNP from each region with GWAS P-value ≤1 × 10–6
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eosinophil activation [42, 44–46, 61–64]. IL13 is an
immunoregulatory cytokine produced by TH2 cells that is
critical to the pathogenesis of allergic asthma, operating
through mechanisms independent of IgE and eosinophils
[65]. GSDMB in the established 17q21 childhood asthma
risk region is potentially involved in pathogenesis via epi-
thelial cell pyroptosis [4, 7, 41, 44, 47, 49, 50, 66]. In asth-
matics, the C11orf30-LRRC32 region is associated with
total serum IgE levels [67]. We did not see evidence of as-
sociation from three of the seven established NHGRI-EBI
asthma SNPs, those found in TSLP, RAD50, and GSDMA.
TSLP has a role in TH2 cell responses associated with in-
flammatory diseases including asthma and COPD [65].
RAD50 has been implicated in allergic airway inflamma-
tion, potentially vial regulation of TH2 cytokine genes,
though the exact mechanism remains to be elucidated
a
b
Childhood Asthma NHW GWAS KIAA1958
Childhood Asthma Meta-analysis GWAS SCHIP1, IQCJ-SCHIP1
Fig. 1 LocusZoom Plot of childhood asthma GWAS variants a from non-Hispanic whites in KIAA1958 and b from the meta-analysis in the region
near SCHIP1 and its read through transcript IQCJ-SCHIP1
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[68]. GSDMA is along with GSDMB and ORMDL3 part of
the complex 17q21.1 locus, more research is needed to
understand the specific interactions of variants in this re-
gion and their role in asthma pathobiology [69].
There was one novel genome-wide significant SNP
associated with childhood asthma in the GWAS,
rs59289606, an intron variant in the protein-coding
gene KIAA1958 at locus 9q32; this SNP is imputed with
Rsq 0.38, which meets our criteria for imputation qual-
ity. KIAA1958 has not been previously associated with
disease pathogenesis [70]. In the AA population, vari-
ants of interest were found in FLJ12825 and PHF14.
FLJ12825 is a non-coding RNA, and PHF14 is a protein
coding gene important in regulation of mesenchymal
cell proliferation specific to lung fibrosis, that has also
been described in newborn respiratory failure and new-
born pulmonary hypertension [71, 72]. Meta-analysis
identified a region of interest in SCHIP1 and its
read-through transcript IQCJ-SCHIP1. SCHIP1 has
been reported along with IL12A as a potential systemic
sclerosis gene which functions in immune regulation
via T cell activity [73].
Limitations
This childhood asthma GWAS used a cohort of adult
smokers at risk for COPD. It is underpowered relative to
the large-scale asthma GWAS that have recently been
published. However, our objective was not to run a novel
asthma GWAS; rather, the goal of this investigation was
to examine self-reported asthma in a population of adult
smokers at risk for COPD. Ideally, we would have been
able to compare this self-reported diagnosis of childhood
asthma to a gold-standard diagnosis, such as childhood
spirometry or medical records, but this primary data in
this cohort of older adults is not available. Notably,
when compared to clinical diagnosis, questionnaire re-
ported asthma history has been shown to have relatively
good agreement and reliability over time [74–76]. It
would have additionally been valuable to use medical re-
cords to assess asthma treatment and control; however,
Table 4 Associations with NHGRI-EBI asthma SNPs in COPDGene childhood asthma GWAS
NHWa Gene SNP Locus Effect Allele OR Rsq Freq (%) P-valueb,d Adj P-valuee
(385 cases, 4979 controls) IL1RL1 rs10197862f 2q12.1 A 1.45 1.00 0.85 0.002 0.011
TSLP rs1837253g 5q22.1 T 1.07 0.75 0.414 1.000
RAD50 rs2244012f 5q31.1 G 1.05 0.78 0.579 1.000
IL13 rs1295686f 5q31.1 T 1.22 0.80 0.026 0.180
C11orf30-LRRC32 rs7130588g 11q13.5 G 1.23 0.64 0.008 0.054
GSDMB rs2305480f 17q21.1 G 1.22 0.44 0.009 0.060
GSDMA rs3894194f 17q21.1 A 1.18 0.94 0.47 0.029 0.201
AAa Gene SNP Locus Effect Allele OR Rsq Freq (%) P-valueb,d Adj P-valuee
(325 cases, 2342 controls) IL1RL1 rs10197862f 2q12.1 A 1.10 0.98 0.74 0.344 1.000
TSLP rs1837253g 5q22.1 C 1.11 0.28 0.283 1.000
RAD50 rs2244012f 5q31.1 G 1.05 0.57 0.603 1.000
IL13 rs1295686f 5q31.1 T 1.16 0.64 0.102 0.717
C11orf30-LRRC32 rs7130588g 11q13.5 G 1.23 0.80 0.035 0.247
GSDMB rs2305480f 17q21.1 G 1.03 0.13 0.817 1.000
GSDMA rs3894194f 17q21.1 G 1.02 0.88 0.69 0.846 1.000
Meta-analysisa Gene SNP Locus Effect Allele OR I2 P-valuec,d Adj P-valuee
(710 cases, 7321 controls) IL1RL1 rs10197862f 2q12.1 A 1.23 70 0.006 0.042
TSLP rs1837253g 5q22.1 C 1.01 45 0.910 1.000
RAD50 rs2244012f 5q31.1 G 1.05 0 0.447 1.000
IL13 rs1295686f 5q31.1 T 1.19 0 0.006 0.043
C11orf30-LRRC32 rs7130588g 11q13.5 G 1.23 0 0.001 0.005
GSDMB rs2305480f 17q21.1 G 1.17 27 0.018 0.125
GSDMA rs3894194f 17q21.1 A 1.10 57 0.113 0.794
Abbreviations: NHGRI-EBI National Human Genome Research Institute - European Bioinformatics Institute; SNP single nucleotide polymorphism; GWAS genome-
wide association study; NHW Non-Hispanic Whites; AA African American; OR odds ratio of the effect allele; Rsq estimation of imputation quality; Freq frequency of
effect allele; I2 heterogeneity index; a Each population was run as an independent analysis, and then combined in the meta-analysis: b Logistic regression based
on case control status; c Fixed effect meta-analysis weighted by inverse variance. d Adjusted for sex, genetic ancestry. e Bonferroni correction for seven tests, SNPs
with adjusted p < 0.05 in Bold. f SNP is in the reported gene, g SNP is near the reported gene
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we note that many of these subjects had childhood
asthma prior to the widespread use of inhaled cortico-
steroids in the US. Additionally, asthma treatment will
not impact the patients’ genotype, so the objectivity of
that measure is maintained. Since COPDGene includes
smokers, we were not able to assess COPD risk among
non-smokers; given that this investigation was focused
on a population with a high COPD risk, including only
smokers is reasonable.
The assessed list of known asthma variants were se-
lected from 600 asthma associations published in the
NHGRI-EBI GWAS catalog, where only eight independ-
ent SNPs were reported in more than one study. An add-
itional set of five pediatric asthma GWAS SNPs from the
TAGC was also examined. We acknowledge that alterna-
tive lists of established asthma SNPs could be proposed. It
is notable that the established asthma variant list was
largely composed of SNPs from European American or
NHW populations, and thus the lack of associations in
the AA population is not unexpected. This also explains
why the combined NHW and AA meta-analysis did not
improve power to detect associations for some of the
SNPs. It would have been desirable to include other popu-
lations with alternative genetic heritage, but COPDGene is
limited to NHW and AA subjects.
Conclusions
Self-report of childhood asthma in adult smokers from
COPDGene identifies a meaningful population who dem-
onstrate the demographic, clinical, and genetic characteris-
tics known to associate with childhood asthma. Compared
to subjects who never had asthma, self-reported childhood
asthmatics were younger, more likely to be of AA race, and
had increased odds of COPD. We showed associations with
known asthma loci in IL1RL1, IL13, LINC01149, near
GSDMB, and in the C11orf30-LRRC32 region. This GWAS
identified a new variant in KIAA1958 associated with child-
hood asthma in NHWs. This study will enhance future
genetic epidemiology research in early-life asthmatics at
risk for COPD and therefore ACO, by establishing the
validity of self-reported asthma in the research setting.
This study emphasizes that clinicians need to consider
childhood asthma when assessing patients at increased
risk for COPD, and that patient self-report is a reliable
method of defining ACO.
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